BI-1347

• Description:

  BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM) . BI-1347 shows anti-tumoral activity[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bi-1347.html

• Purity:

  99.84

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C (N (C) C) CN1N=CC (C2=CC=C (C3=CN=CC4=C3C=CC=C4) C=C2) =C1

• Molecular Formula:

  C22H20N4O

• Molecular Weight:

  356.42

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Harald Engelhardt, et al. New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors.|[2]Hofmann MH, et al. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance. Mol Cancer Ther. 2020 Apr;19 (4) :1018-1030.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK8

• CAS Number:

  2163056-91-3